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Abstract
Background: Recent trends of pneumococcal colonization in the United States, following the
introduction of conjugate vaccination, indicate that non-vaccine serotypes tend to replace vaccine
serotypes. The eventual extent of this replacement is however unknown and depends on serotype-
specific carriage and transmission characteristics.
Methods:  Here, some of these characteristics were estimated for vaccine and non-vaccine
serotypes from the follow-up of 4,488 schoolchildren in France in 2000. A Bayesian approach using
Markov chain Monte Carlo data augmentation techniques was used for estimation.
Results: Vaccine and non-vaccine serotypes were found to have similar characteristics: the mean
duration of carriage was 23 days (95% credible interval (CI): 21, 25 days) for vaccine serotypes and
22 days (95% CI: 20, 24 days) for non-vaccine serotypes; within a school of size 100, the Secondary
Attack Rate was 1.1% (95% CI: 1.0%, 1.2%) for both vaccine and non-vaccine serotypes.
Conclusion: This study supports that, in 3–6 years old children, no competitive advantage exists
for vaccine serotypes compared to non-vaccine serotypes. This is an argument in favour of
important serotype replacement. It would be important to validate the result for infants, who are
known to be the main reservoir in maintaining transmission. Overall reduction in pathogenicity
should also be taken into account in forecasting the future burden of pneumococcal colonization
in vaccinated populations.
Background
Less than 10 Streptococcus pneumoniae (S. pneumoniae)
serotypes, among more than 90, have been included in
the S. pneumoniae conjugate vaccine formulation. Since
these serotypes account for a large part of carriage (almost
80% of all carriage in the United States [1]) and the vac-
cine protects against colonization [2], a reduction in over-
all carriage after vaccination is expected, and has indeed
been observed in vaccinated populations [3]. However,
recent trends of pneumococcal colonization in the United
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States, following the introduction of conjugate vaccina-
tion, indicate serotype replacement [4,5], whereby a
decrease in vaccine serotypes carriage is followed by an
increase in carriage of non-vaccine serotypes. The eventual
extent of this replacement is as yet unknown.
Mathematical models have predicted that replacement
could occur in case of direct competition between sero-
types in the absence of cross-immunity [6-9]. In these
models, the extent of replacement is expected to be impor-
tant if the degree of competition is high; and in this latter
case, all the more that vaccine and non-vaccine serotypes
have the same duration of carriage and transmission rate.
However, this last assumption (same duration and trans-
mission) could be challenged, considering the wide heter-
ogeneity observed in serotype-specific prevalence, in favor
of reduced capacity to colonize in the less frequent sero-
types.
Ekdahl et al. [10] reported that there was no difference in
the duration of carriage among 5 serogroups, 3 of which
are included in the vaccine. Smith et al. [11] found that
average duration of carriage ranged 6.7 to 62.5 days
among 25 serotypes, 6 of which are included in the vac-
cine. However, these variations did not clearly identify
vaccine serotypes as having longer carriage duration.
Reported transmission rates of S. pneumoniae estimated
from household data did not investigate serotype specific
characteristics, nor inclusion in the vaccine [12,13]. While
it has been reported that non-vaccine serotypes may be
less invasive [14], there is currently little information on
carriage and transmission characteristics according to
serotype inclusion in the vaccine. This lack of knowledge
may stem from the difficulty to analyze field data on col-
onization, which generally consist of samples irregularly
spaced in time, and lack information about the times of
colonization and decolonization.
Here, using recent computational-based statistical tech-
niques, we analyze a prospective follow-up study of
schoolchildren in France, with a view to estimating car-
riage and transmission characteristics of S. pneumoniae
serotypes according to inclusion in the vaccine.
Methods
Data
A five month longitudinal study of 3–6-year-old children
in 81 schools, presented in detail elsewhere [15], was con-
ducted from January to May 2000 in France. Oropharyn-
geal pneumococcal colonization was monitored. Swabs
were collected in the schools approximately every month,
for a five month period. The mean time lag between con-
secutive swabs was 37 days (standard deviation: 15 days).
During the observation period, 9,857 swabs were col-
lected for serotyping. Among the 4,488 3–6-year-old chil-
dren attending the schools (88% of the 3–6-year-old
children in the area under study), 2,445 (55%) gave at
least one swab. Among children giving at least one swab,
the mean number of swabs was four (min-max: one –
five). All children attending the schools were included in
the analysis, even those without a single observation dur-
ing the follow-up.
The analysis was restricted to the carriage of the 16 sero-
types that were isolated in at least 30 swabs in the selected
schools. Table 1 presents the results of the serotyping.
The only currently available pneumococcal conjugate vac-
cine is the seven-valent vaccine, which includes serotypes
4, 6B, 9V, 14, 18C, 19F and 23F. Hence, we divided the
serotypes selected for analysis into two groups: vaccine
serotypes, and non-vaccine serotypes. The two groups are
detailed in table 1. Vaccine serotype 4 was not selected for
analysis because it was isolated in 10 swabs only. At the
time of the study, conjugate vaccine had not been intro-
duced in France, so that children participating in the study
were all unvaccinated.
Figure 1 presents data collected in a school participating
in the study. Among the 41 children of the school, 15, 6,
3, 4, 12 and 1 children gave respectively 5, 4, 3, 1 and 0
swabs. While serotype 6A was not detected in the school
at the beginning of the follow-up, a micro-epidemic was
observed during the second half of the follow-up, with at
least 8 children carrying serotype 6A during this time
period.
Table 1: Results of serotyping during follow-up of 4,488 children 
in 81 schools, January-May 2000, France.
Frequency (%)
Serotypes with at least 30 swabs
Vaccine serotypes† 19F 403 (4.1)
6B 313 (3.2)
23F 274 (2.8)
14 191 (1.9)
18C 79 (0.8)
9V 79 (0.8)
Non-vaccine serotypes 6A 281 (2.9)
3 238 (2.4)
19A 212 (2.2)
11A 80 (0.8)
15A 72 (0.7)
15B 54 (0.5)
23A 46 (0.5)
17F 44 (0.4)
10A 42 (0.4)
9L 32 (0.3)
Other serotypes 247 (2.5)
Non-colonized 7,170 (72.7)
Total 9,857 (100.0)
† Serotype included in the 7-valent conjugate vaccine.BMC Infectious Diseases 2006, 6:14 http://www.biomedcentral.com/1471-2334/6/14
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Transmission model
Here, we present a dynamic model for S. pneumoniae
transmission in schools. The model detailed the individ-
ual rate of colonization and decolonization by S. pneumo-
niae for all children attending the schools (even those that
gave no swab at all). In the subsequent section "Estima-
tion of transmission parameters", we show how model
parameters may be estimated from the data.
In the model, we assumed that dual colonization was
impossible (a child colonized by one serotype may not
acquire another unless first clearing). Non-colonized chil-
dren could be colonized within their school (see § Within-
Swabs collected in a school participating in the study Figure 1
Swabs collected in a school participating in the study. "0" indicates that the sample was taken but no serotype was 
detected; otherwise, serotype number is given.
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school acquisition), or in the community (i.e. out of the
school, see § Other assumptions).
Duration of carriage
We assumed that the duration of carriage of a given sero-
type had an Exponential distribution with mean µV for
vaccine serotypes and µU for non-vaccine serotypes. This
particular distribution is in good agreement with observed
data [10].
Within-school acquisition
We considered the school as a dynamic environment, i.e
the number Cs(t) of children colonized by serotype s at
time t was a function of time. We assumed that, for each
child who was not colonized at time t, the individual rate
to acquire serotype s in the school at time t was i) propor-
tional to Cs(t), since this increased opportunities for trans-
mission; and ii) inversely proportional to the size n of the
school to allow for reduced frequency of contacts in each
pair of children in larger schools [16]. With these assump-
tions, the individual rate to acquire serotype s at time t was
β Cs(t)/n, where n was the size of the school (including
children that gave no swab at all) and β corresponded to
pairwise child-to-child transmission rate, irrespective of
the size n of the school. Note that this formulation leads
to an aggregate rate of colonization due to intra-school
transmission of β Cs(t) S(t)/n, where S(t) is the number of
non colonized children, in agreement with the standard
Data augmentation strategy to estimate transmission parameters of S. pneumoniae from the longitudinal follow-up of pneumo- coccal carriage in schools Figure 2
Data augmentation strategy to estimate transmission parameters of S. pneumoniae from the longitudinal fol-
low-up of pneumococcal carriage in schools. The observed data consist of the times when swabs are collected in the 
school. The data are augmented with the times of colonization/decolonization. In the MCMC algorithm, augmented periods of 
carriage may be added/suppressed, split/combined; and the times of colonization/decolonization may change.
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 Carriage in continuous time;
 Compatible with the observation.
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Susceptible-Infectious-Susceptible model [17]. We
denoted the child to child transmission rate βV for vaccine
serotypes, and βU for non-vaccine serotypes.
Other assumptions
We assumed that, during the 5-months follow-up, a non-
colonized child was exposed to a rate αs to acquire sero-
type s in the community, with αs constant over time. It was
also necessary to define the probability that a child carried
serotype s at the beginning of the follow-up by πs. The val-
ues of αs and πs were serotype dependent. Parameters αs
and πs will be considered according to two clusters to be
learnt from the data through the model.
Characterizing transmission from the model
The model was used to calculate the monthly probability
to acquire a serotype in the community, which is 1-exp(-
αs30) for serotype s. It was also possible to calculate the
Secondary Attack Rate (SAR), defined here as the proba-
bility that a colonized child transmits the bacteria to a
non-colonized child of his/her school for a colonization
event. The Secondary Attack Rate combines information
on the mean duration of carriage µ and the child to child
transmission rate β, and therefore allowed investigation
of whether vaccine serotypes had 'globally' a better fitness
for transmission than non-vaccine serotypes. Assuming
that there is no transmission beyond the secondary case
and that there is at maximum one acquisition of carriage
per susceptible during the one month period, the proba-
bility of transmission between two children of a school of
size n is:
where L is the duration of carriage with density f(L)=exp(-
L/µ)/µ and 1 - exp(- β L/n) is the probability that a child
colonized during time period L transmits to a non-colo-
nized child of the school. Eventually, the Secondary
Attack Rate was equal to (1+Nµ -1 β-1)-1 within a school of
size n.
Estimation of transmission parameters
Data augmentation
The transmission model may easily be estimated with
likelihood-based approaches from complete data that
consist of the times of colonization and decolonization
for each child. In practice however, carriage is only
observed at few times, so that the likelihood of the data is
not readily available. Figure 2 illustrates the data augmen-
tation strategy adopted to circumvent this difficulty. It
consists of augmenting the data with a description of col-
onization in continuous time that is compatible with the
observations [13].
Conditional on these augmented times and model param-
eters, the likelihood of the data is available, but since
there is no unique way to choose the augmented times
given the observation, a systematic exploration of the aug-
mented times is necessary for inference. This is performed
by Markov chain Monte Carlo (MCMC) sampling. In the
algorithm, augmented periods of carriage may be added/
suppressed, split/combined; and the times of coloniza-
tion/decolonization may change [13]. Figure 2 presents
two augmented trajectories that are compatible with the
observation and could be explored by our algorithm.
Heterogeneity in the community acquisition rates of serotypes and in 
the probabilities of carriage at the beginning of follow-up
Heterogeneity was allowed in the community acquisition
rates of serotypes and in the probabilities of carriage at the
beginning of follow-up. More precisely, we allowed sero-
types to cluster in two subgroups, not fixed in advance, for
each of these parameters. In the MCMC sampling scheme,
changes in serotypes allocation were proposed independ-
ently for community acquisition rate and probability of
carriage at the beginning of the follow-up.
Bayesian hierarchical framework
The statistical framework has a Bayesian hierarchical
structure [18], with 3 levels:
A) The observation level ensures that the augmented data
are consistent with the observation;
B) The transmission level describes the latent transmis-
sion process (transmission model);
C) The prior level specifies the prior distributions of the
parameters: For the child to child transmission rate β, the
community acquisition rate α and the mean duration of
carriage  µ, we specified vague flat priors consisting of
Exponential distributions with means 105 day-1, 105 day-1
and 105 days, respectively. The prior distribution for the
probability π of carriage at the beginning of the follow-up
was uniform from 0 to 1.
MCMC implementation
The MCMC algorithm was developed in C; the output was
analyzed with R software. The seed used in the simula-
tions was given by the computer clock. We performed
1,000,000 iterations for each run of the MCMC algorithm.
The first 500,000 were discarded as the burn-in period.
The output was then recorded once every 5 iterations to
constitute a sample from the posterior distribution. The
convergence was visually assessed, and tested with the
Geweke criteria [19]. We also checked that estimates were
robust to a change in the initial values.
SAR f L dL =− − ()
∞
∫ 1
0
exp( ( ) βLn /)BMC Infectious Diseases 2006, 6:14 http://www.biomedcentral.com/1471-2334/6/14
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Eventually, the joint posterior distribution of augmented
data, clusters of serotypes and parameters was explored by
MCMC sampling, and characterized by means and equal-
tailed 95% credible intervals (CI). For the community
acquisition rates and the probabilities of carriage at the
beginning of the follow-up, reported results correspond to
the partition of serotypes with the largest posterior proba-
bility.
Results
Table 2 gives the posterior mean (95% CI) of carriage and
transmission parameters of S. pneumoniae.
Durations of carriage
The mean duration of carriage was µV = 23 (95% CI: 21,
25) days for vaccine serotypes and µU = 22 (95% CI: 20,
24) days for non-vaccine serotypes, leading to a relative
mean duration of carriage (µV/µU) equal to 1.06 (95% CI:
0.94, 1.18).
Colonization rate within a school
The child to child transmission rate was βV = 0.046 (95%
CI: 0.042, 0.050) day-1 for vaccine serotypes and βU =
0.051 (95% CI: 0.045, 0.056) day-1 for non-vaccine sero-
types, leading to a relative child to child transmission rate
(βV/βU) equal to 0.91 (95% CI: 0.80, 1.05). In schools of
size 30, 50, and 100, the Secondary Attack Rate was
respectively 3.4% (95% CI: 3.2%, 3.7%), 2.1% (95% CI:
1.9%, 2.2%) and 1.1% (95% CI: 1.0%, 1.2%) for vaccine
serotypes, and 3.6% (95% CI: 3.3%, 3.8%), 2.2% (95%
CI: 2.0%, 2.3%) and 1.1% (95% CI: 1.0%, 1.2%) for non-
vaccine serotypes. The relative Secondary Attack Rate
(SARV/SARU) was 0.97 (95% CI: 0.88, 1.06) irrespective of
the size of the school.
Other parameters
The posterior probability of the partition with largest sup-
port was 84% for the community acquisition rate and
92% for the probability of carriage at the beginning of the
follow-up. Serotypes clustered identically regarding com-
munity acquisition rate and probability of carriage at the
beginning of the follow-up. The first cluster of serotypes
contained 9 serotypes (23A, 17F, 10A, 15B, 9V, 11A, 18C,
15A, 9L). It was characterized by a monthly probability of
colonization in the community estimated at 0.40% (95%
CI: 0.32%, 0.47%) per serotype, and a probability of car-
riage at the beginning of the follow-up equal to 0.48%
(95% CI: 0.40%, 0.57%) per serotype. The second cluster
consisted of 7 serotypes (19A, 14, 3, 6A, 23F, 6B, 19F).
The monthly probability to acquire one of these serotypes
out of the school was 1.40% (95% CI: 1.20%, 1.65%) per
serotype, with a probability of carriage at the beginning of
the follow-up equal to 2.3% (95% CI: 2.1%, 2.5%) per
serotype. Serotypes that were found to have high commu-
nity acquisition rate/probability of carriage at the begin-
ning of the follow-up were those that were the most
prevalent in the schools (191–403 swabs, as opposed to
32–80 swabs for other serotypes).
Discussion
We found that, in 3–6 years old children, the mean dura-
tion of carriage and the child to child transmission rate of
S. pneumoniae was the same for vaccine and non-vaccine
serotypes, from the analysis of a large cohort of school-
children.
Carriage was determined by oropharyngeal swabbing at
each visit. This procedure is known to be less sensitive
than nasopharyngeal swabbing [20]. Therefore, some
samples could be falsely negative, and lead to underesti-
mate the duration of carriage. However, our estimates of
Table 2: Posterior mean and 95% credible interval of transmission parameters of S. pneumoniae according to serotype inclusion in the 
vaccine. Transmission parameters consist of the mean duration of carriage µ, the child to child transmission rate β and the Secondary 
Attack Rate (SAR).
Vaccine serotype* Non-vaccine serotype† Ratio
Mean 95% CI‡ Mean 95% CI‡ Mean 95% CI‡
µ (days) 23 21, 25 22 20, 24 1.06 0.94, 1.18
β (% day-1) 4.6 4.2, 5.0 5.1 4.5, 5.6 0.91 0.80, 1.05
SAR (%)
n = 30 § 3.4 3.2, 3.7 3.6 3.3, 3.8 0.97 0.88, 1.06
n = 50 § 2.1 1.9, 2.2 2.2 2.0, 2.3 0.97 0.88, 1.06
n = 100 § 1.1 1.0, 1.2 1.1 1.0, 1.2 0.97 0.88, 1.06
* Serotypes 6B, 9V, 14, 18C, 19F, 23F which are included in the 7-valent conjugate vaccine were selected for analysis (at least 30 positive swabs). 
Vaccine serotype 4 was not selected for analysis because it was isolated in 10 swabs only.
† Serotypes 6A, 3, 19A, 11A, 15A, 15B, 23A, 17F, 10A, 9L were selected for analysis.
‡ CI, credible interval.
§n, size of the school.BMC Infectious Diseases 2006, 6:14 http://www.biomedcentral.com/1471-2334/6/14
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the mean durations of carriage (about 20 days for 3–6
years old children) are consistent with those reported by
Ekdahl et al. [10]. Melegaro et al. [12] also found a car-
riage duration of 20 days for children ≥ 5 years old, but of
50 days for children <5 years old. This difference could be
explained by the presence of children under 2 years old,
Posterior predictive check Figure 3
Posterior predictive check. Panel a and b: Predictive distribution of the number of consecutive swabs in which the same 
serotype was detected for non-vaccine (panel a) and vaccine (panel b) serotypes. Panel c: predictive distribution of the sero-
type-specific average prevalence given detection of the serotype in the school. Boxplots give quantiles 2.5%, 25%, 50%, 75% and 
97.5% of the distributions; circles indicate observed values. The predictive distributions are derived from 700 epidemics simu-
lated with transmission parameters drawn from the posterior distribution.
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who are known to have the largest durations of carriage
[10] and were not covered by our study, and also by a
coarser characterization of serotypes in Melegaro et al.
[12]. A larger estimate of the duration of carriage (45
days) was found by Auranen et al. [13] for subjects older
than 2 years old. Here again, a possible difference in the
age distributions of the population under study might
explain the differences in the estimates.
Here, we detected no difference between vaccine and non-
vaccine serotypes for durations of carriage, child to child
transmission rates and Secondary Attack Rates among
school age children. These results are consistent with
those of Ekdahl et al. [10] who found no significant differ-
ence between durations of carriage of serogroups when
adjusted for age; but contrast with those of Smith et al.
[11] who concluded that there was a factor of 10 between
the mean durations of carriage of the most/least persistent
serotypes. Swabs were collected weekly in [10]; and
monthly in [11] and in our study (80% of intervals
between paired nasal swab specimens were larger than ≥
28 days in the study of Smith et al.; this proportion is even
larger in our study). Our approach could be used to re-
analyze the data of Smith et al [11] and investigate
whether their results are robust to: i) the possible occur-
rence of decolonization/re-colonization between consec-
utive positive swabs; ii) the inclusion of micro-epidemics
in the stochastic transmission model. Since sensitivity of
oropharyngeal swabbing is not likely to be serotype-
dependent, differences between vaccine and non-vaccine
durations of carriage should not be affected if durations of
carriage were underestimated. Simulation studies showed
that we could have detected differences between durations
of carriage of the order of one week, but also that the sam-
pling interval (approximately 1 month in our study) was
sufficient to estimate durations of carriage in the consid-
ered range (≥18 days). It would be important to investi-
gate if it is still the case with shorter durations of carriage.
Simple statistics from the raw data supported that child to
child transmission rates and mean durations of carriage
were similar across vaccine and non vaccine serotypes.
Figure 3 shows the distribution of the number of consec-
utive swabs in which the same serotype was detected in
the same children. This distribution was the same for non-
vaccine (circle, panel a) and vaccine (circle, panel b) sero-
types, suggesting similar durations of carriage since the
frequency of sampling was not serotype dependent. We
also calculated, for each school and each month during
the follow-up, the serotype-specific prevalence as the ratio
(number of positive swabs for serotype s)/(total number
of swabs) for serotype s. The average prevalence was
expectedly larger for vaccine serotypes (2.1%) than for
non vaccine serotypes (1.1%). But once a serotype was
detected in the school, its average prevalence was 7% irre-
spective of inclusion in the vaccine. This suggests that
inter-individual transmission in schools was similar for
vaccine and non-vaccine serotypes. Next, we performed
posterior  predictive check using simulations from the
transmission model used for analysis (see the Appendix).
Figure 3 gives the distribution of the number of consecu-
tive swabs predicted by the model for non-vaccine (box-
plot, panel a) and vaccine (boxplot, panel b) serotypes,
and the predictive distribution of prevalence given detec-
tion of the serotype (boxplot, panel c). For the 2 criteria,
related respectively to duration of carriage and to micro-
epidemics (~ child to child transmission rate), model pre-
dictions closely match the data.
Infants are known to be the main reservoir in maintaining
transmission. Consequently, the differences we found in
the community acquisition rates could proceed from het-
erogeneity in serotype-specific prevalence in infants. Our
data does not allow to judge whether serotype-specific
prevalence in infants could be compatible with the
absence of differences in the duration of carriage and in
the child to child transmission rate (like it is for 3–6 years
old children).
While the absence of difference between vaccine and non-
vaccine serotypes seems at odds with the large differences
observed in serotypes prevalence, mathematical models
have shown that, in the context of direct competition with
short term immunity [6-9] or in the context of indirect
competition with long term immunity [6], the difference
in serotypes prevalence could be much larger than what
would be expected in the absence of competition. For
example, in [6], competition between 2 serotypes with
close transmission characteristics (basic reproduction
number 2.2 and 1.8 respectively) led to extinction of the
serotype with reduced transmissibility. Temime et al. [9]
have shown that competition between serotypes was suf-
ficient to generate large differences in prevalence accord-
ing to serotypes, even in the absence of difference in
transmission characteristics. While different modes of
competition may influence serotypes equilibrium preva-
lence, replacement may occur only in case of direct com-
petition in the absence of long-term immunity [6]. In this
context, the extent of replacement depends on the degree
of competition, but also on serotype specific transmission
characteristics, which determine the ability of non vaccine
serotypes to re-colonize the ecological niche released by
vaccine serotypes.
In order to explain differences in the prevalence of car-
riage, heterogeneity is required in at least one parameter
among the duration of carriage, the child to child trans-
mission rate and the community acquisition rate. In this
respect, if duration of carriage and child to child transmis-
sion rate had been fixed to the same value for all sero-BMC Infectious Diseases 2006, 6:14 http://www.biomedcentral.com/1471-2334/6/14
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types, differences in the community acquisition rate
would have naturally shown to match the differences in
serotype specific prevalence in the data. However, our
purpose was here to determine whether the data could
indicate which differences were the most likely. To that
end, we imposed that the mean duration and the child to
child transmission rate should be the same among vaccine
serotypes and among non vaccine serotypes, but allowed
for differences between these two classes. In this frame-
work, it is possible to obtain differences in the mean dura-
tion of carriage, or child to child transmission rate,
between vaccine and non-vaccine serotypes, irrespective
of a difference in the community acquisition rate. We
have found, using simulations, that the data and proce-
dure were informative and selective enough to do this:
changes in the mean duration of carriage, in the presence
of heterogeneity in the community acquisition rate, were
identifiable in the framework described.
In this paper, we focused on pneumococcal carriage and
not on pneumococcal acute otitis media or invasive dis-
ease. While our results favour the hypothesis that replace-
ment should follow vaccination, the overall impact on
pneumococcal disease is less clear. In a vaccinated popu-
lation the othopathogenic capacities of the replacing non-
conjugate vaccine type pneumococci have been estab-
lished [21,22]. For invasive diseases, some serotypes not
included in the vaccine appear to be less invasive [14] and
a reduction in incidence could follow the introduction of
the vaccine despite replacement in carriage.
We considered a model in which competition was direct
and prevented dual colonization. This last assumption is
strong since dual colonization is possible [23,24]. How-
ever, given the nature of our data in which at most 1 sero-
type may be detected per swab, this was the only sensible
approach. If information on dual colonization were avail-
able in the data, the approach could easily be extended to
estimate competition parameters as listed by Lipsitch [7].
Our approach, similar to that of Auranen et al. [13],
amounted to consider that in case of dual colonization in
one individual there was a "major" serotype that would be
transmitted. The results should be robust to this assump-
tion unless there was a significant transmission of
"minor" serotypes in case of dual transmission.
In our analysis, we investigated transmission of the 16
serotypes that were the most prevalent in the dataset. We
assumed that individuals carrying less prevalent serotypes
were susceptible to colonization by serotypes under study
(absence of direct competition). This may have an effect
on the duration of carriage estimates as out competition
may have occurred rather than clearance of the serotype
that was originally carried. However, the effect should be
limited since serotypes included in the analysis represent
93% of overall carriage.
Heterogeneity in community acquisition rates and proba-
bilities of carriage at the beginning of the follow-up was
explored by allowing free cluster formation according to
these parameters. The number of clusters was fixed (= 2),
but the composition of the clusters was determined by the
MCMC algorithm. With a number of clusters fixed to 3 or
4, the estimates of the mean durations of carriage and the
child to child transmission rates remained unchanged.
Conclusion
In conclusion, this study supports that, in 3–6 years old
children, no competitive advantage exists for vaccine sero-
types compared to non-vaccine serotypes. This is an argu-
ment in favour of important serotype replacement. It
would be important to validate the result for infants, who
are known to be the main reservoir in maintaining trans-
mission. Overall reduction in pathogenicity should also
be taken into account in forecasting the future burden of
pneumococcal colonization in vaccinated populations.
Abbreviations
CI, Credible Interval;
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S. pneumoniae, Streptococcus pneumoniae;
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Appendix: Simulations
Seven hundred epidemics were simulated from the
model, with transmission parameters for the serotypes
(child to child transmission rate β, community acquisi-
tion rate α and mean duration of carriage µ for each sero-
type) drawn from the posterior  distribution. The
probability of carriage at time 0 was not sampled from the
posterior distribution. Rather, we let the simulation start in
the remote past (t = -1000) with no carriage in the school.
The distribution of carriage at time 0 is therefore only
dependent on the transmission parameters β, α and µ. The
simulations were designed so that field and simulated
data had the same structure: same number of schools and
same number of children per school; same number of
swabs for children j of schools i of both data, collected at
the same times.
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